|
rs10009228
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
A SNP in the alpha9 subunit, the G allele of rs10009228 (alpha9, A>G) shows a significant trend in the combined cohort, indicating that this allele constitutes a risk factor for neoplastic progression.
|
22406075 |
2012 |
|
rs1042028
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Accumulating data indicates that the polymorphism rs9282861 (R213H) is responsible for inefficient enzymatic activity and associated with cancer progression.
|
31835852 |
2019 |
|
rs104893626
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.
|
24711662 |
2014 |
|
rs104894230
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
rs1057519710
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Analysis of a 17-cm malignant GIST in the index patient revealed that it was hemi/homozygous for the germline D820Y mutation, indicating loss of the remaining wild-type KIT allele with tumor progression.
|
16327443 |
2005 |
|
rs1057519771
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
CHMFL-ABL-039 has demonstrated greater efficacies than Imatinib regarding to the anti-proliferation, inhibition of the signaling pathway, arrest of cell cycle progression, induction of apoptosis in vitro and suppression of the tumor progression in vivo in the native and V299L mutated BCR-ABL kinase-driven cells/xenograft models.
|
30894066 |
2019 |
|
rs1057519847
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
|
rs1057519848
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
|
rs11549465
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hypoxia-inducible factor-1 (HIF-1) influences cancer progression and metastasis through various mechanisms, and HIF-1α polymorphisms are reportedly associated with many cancers; however, the associations of HIF-1α P582S and A588T polymorphisms with the risk of digestive system cancer remain inconclusive.
|
24293391 |
2014 |
|
rs11549467
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hypoxia-inducible factor-1 (HIF-1) influences cancer progression and metastasis through various mechanisms, and HIF-1α polymorphisms are reportedly associated with many cancers; however, the associations of HIF-1α P582S and A588T polymorphisms with the risk of digestive system cancer remain inconclusive.
|
24293391 |
2014 |
|
rs11568818
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The -181A→G (rs11568818) polymorphism in the MMP7 promoter modulates gene expression and possibly affects cancer progression.
|
25847246 |
2015 |
|
rs11672691
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found an association of the aggressive PCa-associated allele G of rs11672691 with elevated transcript levels of two biologically plausible candidate genes, PCAT19 and CEACAM21, implicated in PCa cell growth and tumor progression.
|
30033361 |
2018 |
|
rs121434568
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haploinsufficiency of Nkx2-1 enhanced Kras(G12D)-mediated tumor progression, but reduced EGFR(L858R)-mediated progression.
|
23143308 |
2012 |
|
rs121913279
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The results suggest PIK3CA H1047R mutant cells have a selective advantage in breast, contribute to breast cancer susceptibility, and drive tumor progression during breast carcinogenesis, even when present as only a subpopulation of tumor cells.
|
27108388 |
2016 |
|
rs121917887
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
A similar ser120-gly mutation in NME1 has been found in human neuroblastoma, suggesting that mutation in this region may be a general phenomenon related to tumor progression.
|
7794272 |
1995 |
|
rs121918464
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The E76K GOF mutation is the most common and active SHP2 mutation; however, the pathogenic effects and function of this mutation in CRC tumor progression have not been well characterized.
|
29323748 |
2018 |
|
rs1273593548
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
To determine which KRAS effectors were responsible for tumor progression, we created four effector domain mutants (S35, G37, E38 and C40) in G12V-activated KRAS and expressed these alone or with BrafV600E in mouse lungs...
|
24489653 |
2014 |
|
rs1285136498
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Besides earlier described DNA methylation, recent studies implicate bone morphogenic protein and non-steroidal anti-inflammatory drugs in control of S100P expression during tumor progression.
|
20155429 |
2011 |
|
rs1288373809
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data showed that (1) the frequency of C609T NQO1 was significantly increased in TNM stage III HCC patients; (2) no significant association was found between p53 expression and C609T polymorphism of NQO1 gene; and (3) a tumor/non-tumor (T/N) ratio > 1.27 of NQO1 expression revealed by real-time qPCR analyses was positively correlated with poorer survival in patients with tumors >5 cm, suggesting that an increase of NQO1 expression may be an indicator of advanced tumor progression.
|
19688691 |
2009 |
|
rs137852578
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
Human LNCaP cells, extensively used as a model for androgen-dependent prostate tumor, express the androgen receptor (AR) mutant T877A promiscuously transactivated by estrogens and other ligands, which may further facilitate cancer progression.
|
12391264 |
2002 |
|
rs1418810723
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs1443465532
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
These results demonstrate that P125A endostatin inhibits the angiogenic switch during mammary gland adenocarcinoma tumor progression in the C3(1)/Tag transgenic model.
|
12209972 |
2002 |
|
rs145204276
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The allele del of rs145204276 is associated with a remarkably lower incidence of cancer progression and metastasis.
|
29557411 |
2018 |
|
rs1695
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The current data, based on a large cohort (n = 929) of Chinese patients with gastric cancer, suggested that the presence of SOD2 rs4880 and GSTP1 rs1695 genotypes may contribute to cancer progression as well as tumor aggressiveness.
|
22517484 |
2012 |
|
rs17217772
|
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
We performed a case-control study to test the association between two polymorphisms in the hMSH2 gene: an A --> G transition at 127 position producing an Asn --> Ser substitution at codon 127 (the Asn127Ser polymorphism) and a G --> A transition at 1032 position resulting in a Gly --> Asp change at codon 322 (the Gly322Asp polymorphism) and breast cancer risk and cancer progression.
|
16252083 |
2005 |